Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

被引：0
|
作者：
Min Huang
M. Catherine Pietanza
Ayman Samkari
James Pellissier
Thomas Burke
Sheenu Chandwani
Fansen Kong
A. Simon Pickard
机构：
[1] Merck & Co.,Centre for Observational and Real
[2] Inc.,world Evidence
[3] Second City Outcomes Research,undefined
来源：
PharmacoEconomics | 2019年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 116
页数：11
相关论文
共 50 条
  • [1] Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer
    Huang, Min
    Pietanza, M. Catherine
    Samkari, Ayman
    Pellissier, James
    Burke, Thomas
    Chandwani, Sheenu
    Kong, Fansen
    Pickard, A. Simon
    PHARMACOECONOMICS, 2019, 37 (01) : 105 - 116
  • [2] Q-TWiST analysis to assess benefit-risk of pembrolizumab in patients with PD-L1-positive advanced or metastatic NSCLC
    Huang, M.
    Pietanza, M. C.
    Samkari, A.
    Pellissier, J.
    Burke, T.
    Chandwani, S.
    Kong, F.
    Pickard, A. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang
    Ogunniyi, Adebayo
    Barbee, Meagan S.
    Drilon, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (01) : 13 - 20
  • [4] Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
    Mienko, Fiona
    Halmos, Balazs
    Cheng, Haiying
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (12)
  • [5] Advanced non-small cell lung cancer with PD-L1≥50%: Pembrolizumab alone or combined with chemotherapy
    Han, B.
    Han, B.
    Zhang, B.
    Hu, M.
    Wang, Y.
    Yang, Z.
    Zhang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S758 - S759
  • [6] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [7] PD-L1 expression for advanced non-small cell lung cancer patients with cancer cachexia
    Morimoto, Kenji
    Yamada, Tadaaki
    CANCER SCIENCE, 2023, 114 : 1410 - 1410
  • [8] The Value of PD-L1 Expression in metastatic Lymph Nodes of Advanced Non-Small Cell Lung Cancer
    Yang, Haitang
    Hall, Sean R. R.
    Yao, Feng
    CHEST, 2020, 158 (04) : 1785 - 1787
  • [9] Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer
    Sakamoto, Mandy
    Jimeno, Antonio
    DRUGS OF TODAY, 2023, 59 (03) : 169 - 177
  • [10] Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1
    Fasching, P. A.
    Huang, M.
    Haiderali, A.
    Pan, W.
    Hu, P.
    Chaudhuri, M.
    De Tilleghem, C. Le Bailly
    Cappoen, N.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S192 - S193
12345